Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.

Autor: Häntschel M; Department of Internal Medicine VIII, Medical Oncology and Pneumology, Eberhard Karls University, Tübingen, Germany., Niebling J; Department of Internal Medicine II, Oncology, Hematology, Clinical Immunology and Rheumatology, Eberhard Karls University, Tübingen, Germany., Häring A; Department of Internal Medicine II, Oncology, Hematology, Clinical Immunology and Rheumatology, Eberhard Karls University, Tübingen, Germany., Häring MF; Department of Internal Medicine II, Oncology, Hematology, Clinical Immunology and Rheumatology, Eberhard Karls University, Tübingen, Germany., Groß T; Department of Internal Medicine VIII, Medical Oncology and Pneumology, Eberhard Karls University, Tübingen, Germany., Horger M; Department of Radiology, University Hospital and Comprehensive Cancer Center Tübingen, Eberhard Karls University, Tübingen, Germany., Riessen R; Department of Internal Medicine, Medical Intensive Care Unit, Eberhard Karls University, Tübingen, Germany., Haap M; Department of Internal Medicine, Medical Intensive Care Unit, Eberhard Karls University, Tübingen, Germany., Lewis RA; NPARU, University of Worcester, Worcester, UK., Böckeler M; Department of Internal Medicine VIII, Medical Oncology and Pneumology, Eberhard Karls University, Tübingen, Germany., Hetzel J; Department of Internal Medicine VIII, Medical Oncology and Pneumology, Eberhard Karls University, Tübingen, Germany.
Jazyk: angličtina
Zdroj: Thoracic cancer [Thorac Cancer] 2020 Jul; Vol. 11 (7), pp. 2044-2047. Date of Electronic Publication: 2020 May 06.
DOI: 10.1111/1759-7714.13476
Abstrakt: Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR-mutated non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority of patients, severe and even life-threatening side effects have been reported. TKI-induced interstitial lung disease (ILD) has been reported for single cases in modest severity, predominantly in EGFR-TKI pretreated patients. Here, we report a case of successful stabilization of a life-threatening ILD in a de novo T790M mutated NSCLC during first-line treatment with osimertinib. As osimertinib will be used more often in many EGFR-positive NSCLC patients in the future, this potentially life-threatening side effect should receive special attention, especially in first-line treatment.
(© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje